JP5199101B2 - 生体分子の検定を開発するための方法 - Google Patents
生体分子の検定を開発するための方法 Download PDFInfo
- Publication number
- JP5199101B2 JP5199101B2 JP2008535752A JP2008535752A JP5199101B2 JP 5199101 B2 JP5199101 B2 JP 5199101B2 JP 2008535752 A JP2008535752 A JP 2008535752A JP 2008535752 A JP2008535752 A JP 2008535752A JP 5199101 B2 JP5199101 B2 JP 5199101B2
- Authority
- JP
- Japan
- Prior art keywords
- ion
- protein
- parent
- fragment
- proteolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 77
- 238000003556 assay Methods 0.000 title claims description 42
- 150000002500 ions Chemical class 0.000 claims description 279
- 108090000623 proteins and genes Proteins 0.000 claims description 224
- 102000004169 proteins and genes Human genes 0.000 claims description 218
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 189
- 239000012634 fragment Substances 0.000 claims description 162
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 161
- 239000000523 sample Substances 0.000 claims description 99
- 230000007704 transition Effects 0.000 claims description 97
- 230000002797 proteolythic effect Effects 0.000 claims description 94
- 210000002381 plasma Anatomy 0.000 claims description 69
- 238000001360 collision-induced dissociation Methods 0.000 claims description 46
- 238000004949 mass spectrometry Methods 0.000 claims description 29
- 238000002540 product ion scan Methods 0.000 claims description 24
- 238000013467 fragmentation Methods 0.000 claims description 21
- 238000006062 fragmentation reaction Methods 0.000 claims description 21
- 238000004587 chromatography analysis Methods 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 14
- 238000005040 ion trap Methods 0.000 claims description 13
- 239000012472 biological sample Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 230000017854 proteolysis Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003567 ascitic fluid Anatomy 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 210000003756 cervix mucus Anatomy 0.000 claims description 3
- 210000000038 chest Anatomy 0.000 claims description 3
- 210000000416 exudates and transudate Anatomy 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 206010046901 vaginal discharge Diseases 0.000 claims description 3
- 239000013592 cell lysate Substances 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 76
- 238000002474 experimental method Methods 0.000 description 45
- 230000029087 digestion Effects 0.000 description 18
- 238000001514 detection method Methods 0.000 description 16
- 238000005259 measurement Methods 0.000 description 14
- 238000000126 in silico method Methods 0.000 description 13
- 102100037362 Fibronectin Human genes 0.000 description 12
- 108010067306 Fibronectins Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000011068 loading method Methods 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 238000011002 quantification Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108010092694 L-Selectin Proteins 0.000 description 9
- 102000016551 L-selectin Human genes 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 238000000132 electrospray ionisation Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000002731 protein assay Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 101710095339 Apolipoprotein E Proteins 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 108010026552 Proteome Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 3
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 2
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 108050005077 Haptoglobin Proteins 0.000 description 2
- 101800001691 Inter-alpha-trypsin inhibitor light chain Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100032859 Protein AMBP Human genes 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002546 full scan Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 101150026046 iga gene Proteins 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003318 immunodepletion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000005464 sample preparation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102100037529 Coagulation factor V Human genes 0.000 description 1
- 101800000191 Coagulation factor XIIa light chain Proteins 0.000 description 1
- 102400000523 Coagulation factor XIIa light chain Human genes 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 102100024783 Fibrinogen gamma chain Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 108010048325 fibrinopeptides gamma Proteins 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- -1 haptoglobulin β Proteins 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 108010093564 inter-alpha-inhibitor Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004249 ion pair reversed phase high performance liquid chromatography Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010079003 sodium-influx-stimulating peptide Proteins 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Electron Tubes For Measurement (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72718705P | 2005-10-13 | 2005-10-13 | |
| US60/727,187 | 2005-10-13 | ||
| PCT/US2006/040263 WO2007044935A2 (en) | 2005-10-13 | 2006-10-12 | Methods for the development of a biomolecule assay |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009511915A JP2009511915A (ja) | 2009-03-19 |
| JP2009511915A5 JP2009511915A5 (enExample) | 2009-11-26 |
| JP5199101B2 true JP5199101B2 (ja) | 2013-05-15 |
Family
ID=37847242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535752A Expired - Fee Related JP5199101B2 (ja) | 2005-10-13 | 2006-10-12 | 生体分子の検定を開発するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20070231909A1 (enExample) |
| EP (1) | EP1941280A2 (enExample) |
| JP (1) | JP5199101B2 (enExample) |
| CA (1) | CA2625781C (enExample) |
| WO (1) | WO2007044935A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7897405B2 (en) | 2008-02-11 | 2011-03-01 | Thermo Finnigan Llc | Method for identifying the elution time of an analyte |
| JP2009264949A (ja) * | 2008-04-25 | 2009-11-12 | Canon Anelva Technix Corp | イオン付着質量分析装置及びそのイオン付着質量分析方法 |
| WO2010056815A1 (en) * | 2008-11-12 | 2010-05-20 | The Washington University | Simultaneous measurment of the in vivo metabolism of isoforms of a biomolecule |
| EP2199956A1 (en) * | 2008-12-18 | 2010-06-23 | Siemens Aktiengesellschaft | Method and system for managing results of an analysis process on objects handled along a technical process line |
| UA112515C2 (uk) | 2009-06-03 | 2016-09-26 | Дау Аґросаєнсиз Елелсі | Спосіб виявлення присутності двох або більше білків, що становлять інтерес, в зразках рослинного походження |
| JP5408107B2 (ja) * | 2010-11-10 | 2014-02-05 | 株式会社島津製作所 | Ｍｓ／ｍｓ型質量分析装置及び同装置用プログラム |
| EP2715770B1 (en) * | 2011-06-03 | 2021-11-24 | DH Technologies Development Pte. Ltd. | Use of variable xic widths of tof-msms data for the determination of background interference in srm assays |
| JP6046144B2 (ja) * | 2011-09-22 | 2016-12-14 | エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． | 脂肪酸シンターゼタンパク質に対するｓｒｍ／ｍｒｍアッセイ |
| KR101431062B1 (ko) * | 2012-03-08 | 2014-08-21 | (주)바이오메디앙 | 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 |
| US9933416B1 (en) | 2013-07-30 | 2018-04-03 | Pioneer Hi-Bred International, Inc. | Detection and quantification of polypeptides in plants without a reference standard by mass spectrometry |
| JP6176049B2 (ja) * | 2013-10-11 | 2017-08-09 | 株式会社島津製作所 | タンデム四重極型質量分析装置 |
| CA2932378A1 (en) * | 2013-12-24 | 2015-07-02 | Dh Technologies Development Pte. Ltd. | High speed polarity switch time-of-flight spectrometer |
| US9720001B2 (en) * | 2014-05-21 | 2017-08-01 | Thermo Finnigan Llc | Methods for mass spectrometric biopolymer analysis using optimized weighted oligomer scheduling |
| BR112017006419A2 (pt) | 2014-09-30 | 2017-12-19 | Univ Washington | medições cinéticas de tau |
| US20180108521A1 (en) * | 2015-03-11 | 2018-04-19 | DH Technologies Development Pte Ltd. | Method of Increasing Quality of Tandem Mass Spectra |
| EP3334508B1 (en) | 2015-08-13 | 2024-12-18 | Waters Technologies Corporation | Alloy material devices and components |
| US10665442B2 (en) * | 2016-02-29 | 2020-05-26 | Shimadzu Corporation | Mass spectrometer |
| EP3491374B1 (en) | 2016-07-28 | 2024-10-09 | Waters Technologies Corporation | Encapsulated pre-analytic workflow reagents for flow-through devices, liquid chromatography and mass spectrometric analysis |
| US20220099637A1 (en) * | 2018-12-04 | 2022-03-31 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
| US12105093B2 (en) | 2020-07-28 | 2024-10-01 | University Of Washington | Quantitation of GLA proteins by mass spectrometric analysis |
| CN112786105B (zh) * | 2020-12-07 | 2024-05-07 | 中山大学附属第五医院 | 一种宏蛋白质组挖掘方法及其在获取肠道微生物蛋白水解特征中的应用 |
| CN114487207A (zh) * | 2022-02-17 | 2022-05-13 | 杭州市食品药品检验研究院(杭州市食品药品审核查验服务中心、杭州市药品与医疗器械不良反应监测中心) | 一种同时鉴别10种龟鳖甲类中药的液质联用法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4121121A (en) * | 1977-09-13 | 1978-10-17 | Computer Identics Corporation | Follower response control circuit |
| US4361812A (en) * | 1978-12-04 | 1982-11-30 | Radiation Dynamics, Inc. | Voltage stabilized particle accelerator system and method |
| US5209919A (en) * | 1990-07-13 | 1993-05-11 | Regents Of The University Of California | Method of measurement in biological systems |
| US5668708A (en) * | 1996-03-13 | 1997-09-16 | Spellman High Voltage Electronics Corp. | DC power supply with reduced ripple |
| DE69622596T2 (de) * | 1996-10-25 | 2002-11-07 | Merska B.V., Groningen | Nicht-radioaktives rezeptorassay zur quantitativen und qualitativen analyse von spurenmengen eines rezeptorbindierendenanalytes |
| US6428956B1 (en) * | 1998-03-02 | 2002-08-06 | Isis Pharmaceuticals, Inc. | Mass spectrometric methods for biomolecular screening |
| AU765750B2 (en) * | 1998-06-04 | 2003-09-25 | Reprogen, Inc. | Use of cathepsin s in the diagnosis and treatment of endometriosis |
| ATE253126T1 (de) * | 1998-08-25 | 2003-11-15 | Univ Washington | Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen |
| JP2002523114A (ja) * | 1998-08-31 | 2002-07-30 | ユニバーシテイ オブ ワシントン | バイオポリマーの分析のための安定なアイソトープ代謝性ラベリング |
| US6969614B1 (en) * | 1999-02-16 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the isolation and analysis of cellular protein content |
| WO2000052035A1 (en) * | 1999-03-03 | 2000-09-08 | Princeton University | Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics |
| US6629040B1 (en) * | 1999-03-19 | 2003-09-30 | University Of Washington | Isotope distribution encoded tags for protein identification |
| US6391649B1 (en) * | 1999-05-04 | 2002-05-21 | The Rockefeller University | Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy |
| US6936424B1 (en) * | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
| US6770486B1 (en) * | 2000-02-08 | 2004-08-03 | Isis Pharmaceuticals, Inc. | Optimization of ligand affinity for RNA targets using mass spectrometry |
| US6858839B1 (en) * | 2000-02-08 | 2005-02-22 | Agilent Technologies, Inc. | Ion optics for mass spectrometers |
| IL152620A (en) * | 2000-05-05 | 2010-05-17 | Purdue Research Foundation | Affinity selected signature peptides for protein identification and quantification |
| EP1290450A2 (en) * | 2000-06-09 | 2003-03-12 | MDS Proteomics, Inc. | Labeling of proteomic samples during proteolysis for quantitation and sample multiplexing |
| CA2419159A1 (en) * | 2000-08-11 | 2002-02-21 | Agilix Corporation | Ultra-sensitive detection systems |
| US7045296B2 (en) * | 2001-05-08 | 2006-05-16 | Applera Corporation | Process for analyzing protein samples |
| DE10158860B4 (de) * | 2001-11-30 | 2007-04-05 | Bruker Daltonik Gmbh | Massenspektrometrische Proteingemischanalyse |
| GB0305796D0 (en) * | 2002-07-24 | 2003-04-16 | Micromass Ltd | Method of mass spectrometry and a mass spectrometer |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
-
2006
- 2006-10-12 WO PCT/US2006/040263 patent/WO2007044935A2/en not_active Ceased
- 2006-10-12 US US11/580,221 patent/US20070231909A1/en not_active Abandoned
- 2006-10-12 CA CA2625781A patent/CA2625781C/en not_active Expired - Fee Related
- 2006-10-12 EP EP06816949A patent/EP1941280A2/en not_active Ceased
- 2006-10-12 JP JP2008535752A patent/JP5199101B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-01 US US12/572,042 patent/US8187893B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2625781A1 (en) | 2007-04-19 |
| WO2007044935A3 (en) | 2007-10-18 |
| WO2007044935A2 (en) | 2007-04-19 |
| EP1941280A2 (en) | 2008-07-09 |
| JP2009511915A (ja) | 2009-03-19 |
| US8187893B2 (en) | 2012-05-29 |
| CA2625781C (en) | 2014-09-02 |
| US20070231909A1 (en) | 2007-10-04 |
| US20100233815A1 (en) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8187893B2 (en) | Mass spectrometric based assay for presence of a protein without the use of a standard | |
| Gallien et al. | Selected reaction monitoring applied to proteomics | |
| US8809062B2 (en) | Method and apparatus for fractionation-based chemical analyses | |
| US9146213B2 (en) | Method and apparatus for performing retention time matching | |
| US8592752B2 (en) | Techniques for performing retention-time matching of precursor and product ions and for constructing precursor and product ion spectra | |
| CN102762987B (zh) | 测定多肽的序列变体的方法 | |
| US20080206737A1 (en) | Expression quantification using mass spectrometry | |
| Parker et al. | Mass spectrometry in high-throughput clinical biomarker assays: multiple reaction monitoring | |
| CN110678756A (zh) | 使用质谱法对低丰度多肽进行绝对定量的方法 | |
| Hall et al. | Isotope-differentiated binding energy shift tags (IDBEST™) for improved targeted biomarker discovery and validation | |
| Mesmin et al. | Complexity reduction of clinical samples for routine mass spectrometric analysis | |
| Lengqvist et al. | Stable isotope labeling methods in protein profiling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091009 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100916 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111024 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120123 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120418 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130207 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160215 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5199101 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |